Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecotabart vedotin + Gemcitabine in CLDN18.2+ Pancreatic Cancer
NCT07108504Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of tpx-4589 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhongshan Hospital, Fudan University. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
tpx-4589
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07108504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108504.